Semtech makes $34M data center purchase
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
MannKind shares fall 20% despite strong sales in 2025
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
CCIA 2026: Longtime friends find niche in logistics
Matt Lafferty and Brian Gonzalez have been doing things together for a long time. The two met through some like-minded friend groups while Gonzalez was attending Cal Poly San Luis Obispo and stayed connected even when the early parts of their career took them to other places. Even with Lafferty living in Southeast Asia for Read More →
Arcutis closes strong year with continued Zoryve momentum
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Angitia Bio raises $130M in Series D round
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Atara receives FDA rejection, future uncertain
The bad news just keeps coming for Thousand Oaks-based Atara Biotherapeutics. Nearly a year after the biotechnology company laid off 50% of its workforce after one rejection from the U.S. Food and Drug Administration, Atara received another one on Jan. 12. In this notice, Atara, a company specializing in developing transformative therapies for patients with Read More →
Teledyne shares pop 10% after strong year-end earnings
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
